Maria Yuryevna Kovaleva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maria Yuryevna Kovaleva has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- A. S. Korobkina
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation
1 shared publication - A.A. Mochalova
Center for Expertise and Quality Control of Medical Care
1 shared publication - N. I. Zhuravleva
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation
1 shared publication - Olga A. Sukhorukikh
Center for Expertise and Quality Control of Medical Care
1 shared publication - U. N. Dmitrieva
Center for Healthcare Quality Assessment and Control
1 shared publication V. K. Fedyaeva
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation; Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education
1 shared publication
Latest Publications
- 1 December 2019
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- No. 4 (38),p. 8-17
The Assessment of Potential Benefit and Risk Balance in the Process of Clinical Practice Guidelines Development and Grading the Evidence
Aim of the study. A review of international practice of “benefit-risk” ratio assessment in the process of clinical practice guidelines (CPG) development; assessment of its acceptability for Russian Federation. Material and methods. We analyzed official methodological guides of the GRADE working group and information from the websites of the professional associations, indicated on the official GRADE website. Additionally, the review of methods of quantitative assessment of risk-benefit ratio was conducted. The search was performed in Pubmed and Embase in April 2019, according to the queries “benefit-risk guidelines”, “balance of benefits and harm”, “risk-benefit guidelines”. Results. The “benefit-risk” ratio assessment is an important component in the development of CPG, however, there were no universal transparent methods for it: in foreign CPG, the “benefit-risk” ratio for medical interventions is determined by the expert group consensus. There were also identified quantitative methods for assessing this ratio, currently not used in the process of the CPG development. Conclusion. We have not identified universal transparent validated quantitative methods for assessing the “benefit-risk” ratio for medical interventions in CPG. Still many quantitative, semi-quantitative and qualitative methods for analyzing this ratio were found in the literature. Thus it seems appropriate to analyze international experience further, to evaluate the advantages and disadvantages of all assessment systems and to test their acceptability for the development of CPG in the Russian Federation.
- 1 December 2019
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- No. 4 (38),p. 8-17
The Assessment of Potential Benefit and Risk Balance in the Process of Clinical Practice Guidelines Development and Grading the Evidence
Aim of the study. A review of international practice of “benefit-risk” ratio assessment in the process of clinical practice guidelines (CPG) development; assessment of its acceptability for Russian Federation. Material and methods. We analyzed official methodological guides of the GRADE working group and information from the websites of the professional associations, indicated on the official GRADE website. Additionally, the review of methods of quantitative assessment of risk-benefit ratio was conducted. The search was performed in Pubmed and Embase in April 2019, according to the queries “benefit-risk guidelines”, “balance of benefits and harm”, “risk-benefit guidelines”. Results. The “benefit-risk” ratio assessment is an important component in the development of CPG, however, there were no universal transparent methods for it: in foreign CPG, the “benefit-risk” ratio for medical interventions is determined by the expert group consensus. There were also identified quantitative methods for assessing this ratio, currently not used in the process of the CPG development. Conclusion. We have not identified universal transparent validated quantitative methods for assessing the “benefit-risk” ratio for medical interventions in CPG. Still many quantitative, semi-quantitative and qualitative methods for analyzing this ratio were found in the literature. Thus it seems appropriate to analyze international experience further, to evaluate the advantages and disadvantages of all assessment systems and to test their acceptability for the development of CPG in the Russian Federation.
- 1 December 2019
- Published by Joint-Stock Company Chicot in Remedium
- No. 1-2
Клинические рекомендации. История создания и развития в Российской Федерации и за рубежом
The article provides an overview of the history of the development of clinical guidelines, as well as highlights the main provisions of the legal status of clinical guidelines in health system of Russian Federation and foreign health systems.
- 1 December 2019
- Published by Joint-Stock Company Chicot in Remedium
- No. 1-2
Клинические рекомендации. История создания и развития в Российской Федерации и за рубежом
The article provides an overview of the history of the development of clinical guidelines, as well as highlights the main provisions of the legal status of clinical guidelines in health system of Russian Federation and foreign health systems.
- Open Access
- 28 October 2019
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (3) , 239-245
Regulatory and legal status of clinical guidelines and their role in the quality control of medical care in countries of the European Union, North America and Asia
Regulatory and legal status of clinical guidelines and their role in the quality control of medical care in countries of the European Union, North America and Asia
- 28 October 2019
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 12 (3) , 239-245
Open AccessRegulatory and legal status of clinical guidelines and their role in the quality control of medical care in countries of the European Union, North America and Asia
Regulatory and legal status of clinical guidelines and their role in the quality control of medical care in countries of the European Union, North America and Asia